Comparison of health technology assessments for digital therapeutics in Germany, the United Kingdom and France.

ABSTRACT:

Objective

Digital therapeutics (DTx) are promising technologies. However, current assessment and access frameworks, when they exist, are heterogeneous and fragmented. We analysed and compared health technology assessment (HTA) criteria for DTx across European countries that had assessed the same DTx products. This allowed us to conduct a direct comparison of these countries' DTx assessment frameworks.

Methods

A scoping review identified HTA DTx documents from European HTA bodies with specific DTx frameworks in place. The HTAs of the same DTx products assessed across multiple countries were then extracted and analysed.

Results

Deprexis and Velibra were the only DTx products assessed by multiple countries: Deprexis, indicated for depression, was assessed by Germany, the

SUBMITTER: Arca E 

PROVIDER: S-EPMC11752730 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature